Celsion Corporation Stock News

In a report released yesterday, Hartaj Singh from Oppenheimer maintained a Buy rating on Celsion (CLSN), with a price target of $9.00. The company's

In a report released yesterday, Hartaj Singh from Oppenheimer maintained a Buy rating on Celsion ( CLSN – Research Report ), with a price target of $9.00 . The company’s shares closed last Monday

Q4 2019 Celsion Corp Earnings Call

NEW YORK, NY / ACCESSWIRE / March 26, 2020 / Celsion Corp. (NASDAQ:CLSN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 26, 2020 at 11:00 AM E

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 25.) Ra Pharmaceuticals Inc (...

Celsion Corporation (CLSN), a leading oncology drug development company, today jointly announced with Medidata, a Dassault Systèmes company, that examining matched patient data provided by Medidata i

Enters 2020 with a Strong Balance Sheet and an Advancing Clinical Pipeline Conference Call Begins at 11:00 a.m. Eastern Time on Thursday March 26, 2020.

Celsion Corporation (CLSN), a leading oncology drug development company, today announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has recommended that GEN-1 b

Mylan resurrected an old medicine for COVID-19 treatment. Lexicon shuts Zynquista study. Celsion reports positive cancer data.

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter. Biotech stocks went on a roller...

Company to Provide Update on its Phase III OPTIMA Study in Primary Liver Cancer and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J., March 19, 2020 --.